Abstract
The COVID-19 outbreak has become the worst pandemic in at least a century. To fight this disease, a global effort led to the development of several vaccines at an unprecedented rate. There have been, however, several logistic issues with its deployment, from their production and transport, to the hesitancy of the population to be vaccinated. For different reasons, an important amount of individuals is reluctant to get the vaccine, something that hinders our ability to control and - eventually - eradicate the disease. In this work, we analyze the impact that this hesitancy might have in a context in which a more transmissible SARS-CoV-2 variant of concern spreads through a partially vaccinated population. We use age-stratified data from surveys on vaccination acceptance, together with age-contact matrices to inform an age-structured SIR model set in the US. Our results clearly show that higher vaccine hesitancy ratios led to larger outbreaks. A closer inspection of the stratified infection rates also reveals the important role played by the youngest groups. Our results could shed some light on the role that hesitancy will play in the near future and inform policy-makers and the general public of the importance of reducing it.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A. dM., A. A and Y.M. acknowledge partial support from the Government of Aragon and FEDER funds, Spain through grant E36-20R (FENOL), and by MINECO and FEDER funds (FIS2017-87519-P). A. dM is funded by an FPI Predoctoral Fellowship of MINECO. A.A. and Y.M. acknowledge support from Banco Santander (Santander-UZ 2020/0274) and the financial support of Soremartec S.A. and Soremartec Italia, Ferrero Group. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB is needed for this research study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This article has no additional data.